TAK-063 Size:Solid 10 mg Selective inhibition of carboxylesterases by

Selective inhibition of carboxylesterases by isatins

In phase 1 and 2 clinical studies

high-affinity

Solubility: DMSO: 125 mg/mL (477

ME0328 enhances CRISPR-Cas9-mediated HER2 mutation frequency

TAK-063 Size:Solid 10 mg Selective inhibition of carboxylesterases byTAK 063, also known as Balipodect., is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK 063 is currently being evaluated in clinical trials for the treatment of schizophrenia. Phosphodiesterase 10A (PDE10A) is a cAMP cGMP phosphodiesterase highly expressed in medium spiny neurons (MSNs) in the striatum. TAK 063 represents a promising drug for the treatment of schizophrenia with potential for superior safety